HOME HELP SUBSCRIBE ARCHIVE SEARCH TABLE OF CONTENTS FEEDBACK EDITORIAL BOARD ABOUT DOC NEWS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

Services Email this article to a friend Similar articles in this journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by de Jesus Rangel, N. Search for Related Content PubMed Articles by de Jesus Rangel, N. Social Bookmarking                What's this?

TALKING BACK ON ROSIGLITAZONE

The American Mission Hospital Manama Bahrain

Regarding "Talk Back: Gauging the Rosiglitazone Response" (DOC News, August 2007, page 15), the response has been appropriate. We need to be told the truth. One should not expect drug companies to come clean and, worse, many have the "experts" on their "payrolls" (I mean the cash or in kind types).

The response of many of the latter from the medical fraternity has been pathetic and shameful. As conscientious doctors, why not follow the guiding principle of "do no harm." The thiazolidinediones have not been proven to have any long-term benefits and have the potential for harm... at least as far as congestive heart failure is concerned, if not for acute myocardial infarction.

No patient is capable of making a decision on continuing or stopping the medication. That should be done by the doctor, and the best option is to discontinue and take appropriate action should the [blood glucose] start rising. And, of course, don't start any patient on these medications.

Footnotes

For more "Talk Back" responses on rosiglitazone, see "A Much-Disputed Drug," page 14.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

Services Email this article to a friend Similar articles in this journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by de Jesus Rangel, N. Search for Related Content PubMed Articles by de Jesus Rangel, N. Social Bookmarking                What's this?